NextPlat (NXPL) Net Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
NextPlat (NXPL) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | -117.27% |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | -367.42% |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | 34.03% |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | -514.66% |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | -3.47% |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | -27.08% |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | - |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 1,005.12% |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | - |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 189.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 189.31% |
| Mar 31, 2026 | -22.98% |
| Dec 31, 2025 | 51.64% |
| Sep 30, 2025 | 39.82% |
| Jun 30, 2025 | -177.34% |
| Mar 31, 2025 | 19.43% |
| Dec 31, 2024 | -5,225.00% |
| Sep 30, 2024 | -179.09% |
| Jun 30, 2024 | -65.25% |
| Mar 31, 2024 | -27.92% |
| Dec 31, 2023 | -100.13% |
| Sep 30, 2023 | 172.20% |
| Jun 30, 2023 | 375.36% |
| Mar 31, 2023 | -146.00% |
| Dec 31, 2022 | 5,076.79% |
| Sep 30, 2022 | -396.39% |
| Jun 30, 2022 | -110.21% |
| Mar 31, 2022 | 2,830.58% |
| Dec 31, 2021 | 284.21% |
| Sep 30, 2021 | 420.27% |